PRQR Dividend: ProQR Therapeutics NV Yield Insights

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	16	19	9	4	2	9
Revenue Growth (YoY)	-24%	111%	125%	100%	-78%	800%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	15	13	15	18	16	13
Research & Development	45	34	23	48	40	36
Operating Expenses	60	50	41	69	59	51
Other Non Operating Income (Expenses)	--	0	0	--	--	--
Pretax Income	-42	-27	-27	-64	-61	-46
Income Tax Expense	0	0	0	0	0	0
Net Income	-42	-27	-28	-65	-61	-46
Net Income Growth	83%	-4%	-56.99%	7%	33%	-18%
Shares Outstanding (Diluted)	105.34	86.08	81.01	71.64	64.18	50.06
Shares Change (YoY)	28.99%	6%	13%	12%	28%	22%
EPS (Diluted)	-0.4	-0.32	-0.34	-0.91	-0.96	-0.93
EPS Growth	39%	-7%	-62%	-5%	3%	-33%
Free Cash Flow	-49	-37	20	-69	-26	-47
Free Cash Flow Per Share	-0.46	-0.42	0.24	-0.96	-0.4	-0.93
Gross Margin	--	--	--	--	--	--
Operating Margin	-275%	-157.89%	-344.44%	-1,600%	-2,850%	-466.66%
Profit Margin	-262.5%	-142.1%	-311.11%	-1,625%	-3,050%	-511.11%
Free Cash Flow Margin	-306.25%	-194.73%	222.22%	-1,725%	-1,300%	-522.22%
EBITDA	-42	-28	-29	-62	-55	-40
EBITDA Margin	-262.5%	-147.36%	-322.22%	-1,550%	-2,750%	-444.44%
D&A For EBITDA	2	2	2	2	2	2
EBIT	-44	-30	-31	-64	-57	-42
EBIT Margin	-275%	-157.89%	-344.44%	-1,600%	-2,850%	-466.66%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

ProQR Therapeutics NV (PRQR) Price